Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621504 | 0.83 | NR4A2 (1.00) | NR4A2ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1092934 | 0.83 | NR4A2 (1.00) | NR4A2ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4685270 | 0.83 | NR4A2 (0.57) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL1558956 | 0.81 | POLB (0.68) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL14828742 | 0.81 | ALDH1A1 (0.63) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL6098691 | 0.81 | CNR2 (0.60) | NR4A2ALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL8804371 | 0.81 | NR4A2 (0.55) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL20380141 | 0.81 | NR4A2 (0.55) | NR4A2SMN1; SMN2POLBLMNAMAPT | |
| SCHEMBL8803982 | 0.80 | ALDH1A1 (0.61) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL3721490 | 0.80 | ALDH1A1 (0.61) | NR4A2ALDH1A1SMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543282-B2 | Targeted peptide conjugates | MARKER GENE TECHNOLOGIES, INC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180207287-A1 | TARGETED PEPTIDE CONJUGATES | MARKER GENE TECHNOLOGIES, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180207287-A1 | TARGETED PEPTIDE CONJUGATES | MARKER GENE TECHNOLOGIES, INC. | 2018-07-26 | — | — | US | disclosed |
| WO-2018132636-A1 | [18F]MALEIMIDE-BASED GLYCOGEN SYNTHASE KINASE-3BETA LIGANDS FOR POSITRON EMISSION TOMOGRAPHY IMAGING AND RADIOSYNTHESIS METHOD | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-07-19 | — | — | WO | disclosed |
| CN-103130790-A | 3-benzo isoxazole-4-benzpyrole maleimide derivative and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2013-06-05 | — | — | CN | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-1774265-A | Medicine for nerve regeneration | KYOWA HAKKO KOGYO KK (JP) | 2006-05-17 | — | — | CN | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005014584-A9 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-06-23 | — | — | WO | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| WO-2005014584-A1 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005000836-A1 | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
| WO-1998007693-A1 | SYNTHESIS OF BISINDOLYLMALIMIDES | ELI LILLY AND COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | NR4A2 1147/4885ALDH1A1 892/4885SMN1; SMN2 21/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | NR4A2 4254/4885ALDH1A1 3744/4885SMN1; SMN2 1884/4885 |
| US-20180207287-A1 | TARGETED PEPTIDE CONJUGATES | VCP, NLN, GOLT1B | NR4A2 3944/4885ALDH1A1 4042/4885SMN1; SMN2 1407/4885 |
| US-10543282-B2 | Targeted peptide conjugates | VCP, NLN, GOLT1B | NR4A2 3944/4885ALDH1A1 4042/4885SMN1; SMN2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.